Skip to main content

CMU Health offers transcranial magnetic stimulation for individuals with treatment-resistant depression. TMS is a non-invasive therapy that uses electromagnetic pulses to induce electrical activity in those parts of the brain that are underactive in depressed patients. The magnetic coils are placed against the patient’s head during a session. 

How effective is TMS therapy?

Effectiveness rates for TMS are estimated to be up to 62% for remission and up to 83% for reduction in symptoms by at least 50% for those who fully complete a course of TMS (Sackeim, et al., 2020). Medication treatment, generally estimated from the STAR-D trial, is up to 53% for reduction in symptoms by at least 50% and with full remission only seen in 40% of patients after two medication trials (Gaynes, et al., 2009).

Am I a candidate for TMS therapy?

We currently offer TMS to adult patients (ages 18 and up) who have not responded to standard treatments for major depression. These people have what is called treatment-resistant depression. If you are interested in TMS, you can meet with one of our clinicians to carefully review your medical history, current symptoms, and past treatments.

To be eligible for TMS treatment, you must not have:

  • Epilepsy or another seizure disorder.
  • Any metal implants in the skull.

How many TMS treatment sessions do you need?

The first session for treatment is 60 minutes, with subsequent treatment sessions between 20 to 30 minutes.

Most people start to feel better after 10 to 15 treatment sessions, which is equal to about two to three weeks of treatment. 

Key points about TMS therapy

  • Non-invasive, no anesthesia
  • FDA approved for treatment of major depression and obsessive compulsive disorder
  • Free from common antidepressant drug side effects such as weight gain and sexual dysfunction
  • Outpatient procedure

Clinicians to oversee the TMS clinic

  • Dr. Kai Anderson
  • Dr. Mohammad Jafferany
  • Dr. Mindy Prows
  • Dr. Dianne Plath


Dr. Mohammad Jafferany is Professor of Psychiatry at Central Michigan University. He has combined training in Dermatology and Psychiatry. He is past president and current Executive Secretary of Association for Psychocutaneous Medicine of North America. He has more than 170 scholarly texts and publications to his credit on various psychodermatologic topics. He is the co-editor and author of books on Pediatric Psychodermatology, Geriatric Psychodermatology, Stress and skin disorders, Psychotrichology, Trichotillomania and authored two books on Essentials of Psychodermatology and Handbook of Psychodermatology, which is translated into Russian, Chinese and Turkish languages. He has written numerous chapters on psychocutaneous disorders in many textbooks. He has conducted International Psychodermatology workshops and Master Courses in different parts of the world. He is a researcher, writer, lecturer, and invited speaker at various national and international conferences on Psychodermatology around the world. Psychiatric aspects of skin and hair disease and skin picking are his areas of interest and expertise.